



Statin Use in Persons with Diabetes (SUPD) 2024

Measure Description

Percentage of patients with diabetes, ages 40–75, who fill at least one statin or statin combination medication, in any strength or dose, using their Part D benefit during 2024.

*Patients with diabetes are defined as those who have at least 2 fills of diabetes medications during the measurement year.

Required Exclusions

Patients are excluded from the measure if they meet any of the following during 2024:

- Patients in hospice or using hospice services
- End-stage renal disease (ESRD)
- Beneficiaries with rhabdomyolysis or myopathy
- Pregnancy, lactation or fertility
- Cirrhosis
- Pre-diabetes
- Polycystic ovary syndrome (PCOS)

Actions

- In order to exclude patients from this measure who cannot tolerate statin medications, a claim **MUST** be submitted annually using the appropriate ICD-10-CM code.
- Prescriptions must be filled through Part D insurance to close this care opportunity.
- Prescribe at least one statin medication during 2024 to patients diagnosed with diabetes. Remember, medication samples are not captured as a billed pharmacy claim and do not close the SUPD gap.
- Patients who also have ASCVD fall into the SPC measure. This measure may overlap. Remember with the SPC measure, the patient must have a moderate-high intensity statin.
- Consider intermittent dosing ie. QOD, 3X/week, etc., a lower dose statin than previously attempted
- Consider 90-100 day supplies

Exclusion Codes

Cirrhosis– K70.30, K70.31, K71.7, K74.3, K74.4, K74.5, K74.60, K74.69

Pregnancy and/or lactation– O00.101, O00.102, O00.109, O00.111, O00.112, O00.119, O00.201, O00.202, O00.209, etc.

Polycystic Ovarian Syndrome– E28.2

Prediabetes– R73.03

Other abnormal blood glucose– R73.09

Drug induced myopathy– G72.0

Other specified myopathies– G72.89

Myopathy, unspecified– G72.9



From Volume
To Value,
With Care.



Other myositis– M60.80, M60.819, M60.829, M60.839, M60.849, M60.859, M60.869, M60.879

Myositis, unspecified– M60.9

Rhabdomyolysis– M62.82

***Adverse effect of antihyperlipidemic and antiarteriosclerotic drugs, initial encounter**– T46.6X5A

*The condition must be reflected as a ‘history of’ in the medical record and it does not need to occur during the same year the code is billed. These exclusion codes do not guarantee payment and are only used to close the SUPD measure.

Resources

Pharmacy Quality Alliance (PQA) 2023—**PQA typically releases new measures specifications from Feb-March 2024. This tip sheet will be updated upon release of those specifications.**

QUESTIONS? Please reach out to **EMAIL:** carepartnersquality@privahealth.com